Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
06/2010
06/01/2010CA2309925C Recombinant vaccines comprising immunogenic attenuated bacteria having rpos positive phenotype
06/01/2010CA2221495C Methods and uses for apoptin
05/2010
05/27/2010WO2010060031A1 Treatment of diseases, disorders or conditions of the lung using placental cells
05/27/2010WO2010059829A2 Compositions and methods for triggered release rna therapeutics
05/27/2010WO2010059706A2 Translation factors as anti-aging drug targets
05/27/2010WO2010059004A2 Chemical inhibitor of p53-snail binding and pharmaceutical composition for treating cancer disease containing same as its active ingredient
05/27/2010WO2010058824A1 Substance for regulating differentiation into mesenchymal cell, and use thereof
05/27/2010WO2010058572A1 Methods for diagnosing or treating prostate cancer
05/27/2010WO2010058097A1 Truncated cd20 protein, deltacd20
05/27/2010WO2010057501A1 Priming of an immune response
05/27/2010WO2010019914A3 Anti-arrhythmia agents, methods of their use, methods for their identification, and kits thereofre
05/27/2010WO2010002465A3 Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase
05/27/2010WO2009140649A3 Rab3b for the treatment and prevention of parkinson's disease
05/27/2010WO2009061003A3 Nucleic acid complex and nucleic acid delivery composition
05/27/2010US20100130729 Mu-1, member of the cytokine receptor family
05/27/2010US20100130728 Taci-immunoglobulin fusion proteins
05/27/2010US20100130417 Transforming growth factor alpha hii
05/27/2010US20100129901 Hepatitis c virus vaccine
05/27/2010US20100129824 Distinguishing pca3 messenger rna species in benign and malignant prostate tissues
05/27/2010US20100129384 Taci-immunoglobulin fusion proteins
05/27/2010CA2743573A1 Treatment of diseases, disorders or conditions of the lung using placental cells
05/27/2010CA2743229A1 Priming of an immune response
05/26/2010EP2189475A2 Fibroblast growth factor-like polypeptides
05/26/2010EP2189166A1 Methods and materials for treating and diagnosing kallikrein-6 related inflammatory conditions
05/26/2010EP2188379A1 Complexes of rna and cationic peptides for transfection and for immunostimulation
05/26/2010EP2187898A1 Use of the cyp46a1 gene for the treatment of alzheimer's disease
05/26/2010EP2187896A2 Micro-rnas that control myosin expression and myofiber identity
05/26/2010EP1424998B1 Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
05/26/2010EP1272665B1 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
05/26/2010EP1144642B1 Compounds and methods for treatment and diagnosis of chlamydial infection
05/26/2010EP1037916B1 Erythrovirus and its applications
05/26/2010CN1961961B A pharmaceutical formulation and preparation process thereof
05/26/2010CN1880457B Ad6 recombinant nucleic acid
05/26/2010CN1833027B Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
05/26/2010CN1831119B Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
05/26/2010CN1829796B Novel full-length genomic RNA of Japanese encephalitis virus, infectious JEV cDNA therefrom, and use thereof
05/26/2010CN1816626B Antisense oligonucleotide having anticancerous activity
05/26/2010CN1791433B DNA vaccines against tumor growth and methods of use thereof
05/26/2010CN1671407B Compositions and methods for treating diabetes
05/26/2010CN1665933B Immunoconjugates for the treatment of tumours
05/26/2010CN1604795B Combination motif immune stimulatory oligonucleotides with improved activity
05/26/2010CN1578678B Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
05/26/2010CN1468308B Anti-TNF antibodies, compositions, methods and uses
05/26/2010CN1425066B Novel stra6 polypeptides
05/26/2010CN101715489A Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
05/26/2010CN101712965A Japanese encephalitis virus JEV replicon vector and application thereof
05/26/2010CN101712949A Gm-negative ehv-mutants without heterologous elements
05/26/2010CN101712710A LMP1targeted oligonucleotide and application thereof serving as radiotherapeutic sensitizer
05/26/2010CN101711878A Application of ssrA of staphylococcus aureus in preventing and treating staphylococcus aureus infection
05/26/2010CN101711877A Chitosan vehicle and method for making same
05/26/2010CN101711864A gm-negative ehv-mutants without heterologous elements
05/26/2010CN101711862A Medicine target spot relevant to inflammatory diseases and application thereof
05/26/2010CN101711861A bacterial virulence factors and uses thereof
05/26/2010CN101711859A Application of Hfq protein of staphylococcus aureus in preventing and treating staphylococcus aureus infection
05/26/2010CN101338313B Resistance gene of microtus fortis to schistosoma japonicum and encoded polypeptide thereof
05/26/2010CN101186925B General-purpose highly effective eukaryon expression carrier p3I-GFPN and mastitis-resisting transgene carrier constructed by the same
05/26/2010CN101182532B Bifidobacteria-bacillus coli shuttle expression carrier pBES, bifidobacteria-ETEC CFA/I recombinant vector and uses thereof
05/26/2010CN101147807B Substances for preventing and treating autoimmune diseases
05/26/2010CN101143895B Polypeptide with tumour targeting effects and preparation method thereof
05/26/2010CN101100672B Modified HPV E6-E7 fusion gene and coding protein thereof
05/26/2010CN101067139B RNAi vector and its application
05/26/2010CN101057976B Substances for preventing and treating autoimmune diseases
05/26/2010CN101040847B Nanometer medicine agent produced by hydrogenated castor oil and the technique of preparing the same
05/25/2010US7723564 Compositions and methods for modulation of KSR1 and KSR2 interactions
05/25/2010US7723510 MicroRNA molecules
05/25/2010US7723509 Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to target tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; biodrugs
05/25/2010US7723508 Modulation of apolipoprotein (A) expression
05/25/2010US7723501 polynucleotides tht code for Bcl-2 associated athanogenes (BAG), a family of proteins that can regulate protein folding, useful in modulating chaperone protein activity
05/25/2010US7723500 Containing unmethylated CpG dinucleotides; redirection of a Th2 response to a Th1 response; atopic diseases, dermatitis; booster vaccines
05/25/2010US7723496 Tumor antigen for diagnosis and treatment of cell proliferative disorders
05/25/2010US7723479 BSL3 polypeptides
05/25/2010US7723313 via pigment epithelium derived growth factor; inhibition of neuroblastoma growth
05/25/2010US7723312 heat shock protein 27 inhibitors; RNA interference; nuclease resistance
05/25/2010US7723293 administering to the heart of subject in need of increased capillary density in the heart a trk receptor ligand in an amount effective to increase capillary density in the heart, said trk receptor ligand being selected from the group consisting of brain-derived neurotrophic factor, NT-3, and NT-4.
05/25/2010US7723288 Methods and compositions for the treatment of neurological disease
05/25/2010US7723111 Anticancer agents; autoimmune disease
05/25/2010US7723096 Agonist peptides of carcinoembryonic antigen (CEA) and nucleic acid sequences encoding the agonist peptides
05/25/2010US7723094 Recombinant influenza vectors with a polII promoter and ribozymes for vaccines and gene therapy
05/25/2010US7723035 detecting a reduction in gene copy number, by determining gene mutational status, or by detecting a reduction in the RNA transcribed from these genes; inhibition of neoplastic or tumorigenic growth of cancers such as chronic lymphocytic leukemia or prostate cancer cells
05/25/2010US7723022 Oligonucleotide containing activated lymphocytes; antibody therap y; skin disorders; antiallergens; respiratory system disorders
05/25/2010US7722883 Genetic vaccine against PWD circovirus
05/25/2010US7722872 Treatment of cancer with antibodies to costimulating polypeptide of T cells
05/25/2010US7722861 Attenuated Mycobacterium tuberculosis vaccines
05/25/2010US7722860 administering to animal or bird a live protozoan parasite that is genetically engineered to disrupt a stage-specific gene function that is required by the protozoan parasite to establish a secondary infection in the vertebrate host; protozoan parasites belong to the phyla Apicomplexa and Kinetoplastida
05/25/2010CA2376666C Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications
05/25/2010CA2375727C Cytofectin dimers and methods of use thereof
05/25/2010CA2361892C Treatment of tumors with genetically engineered herpes virus
05/25/2010CA2321964C Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant virus
05/25/2010CA2223837C Aav transduction of myoblasts
05/25/2010CA2199715C Novel implant and novel vector for the treatment of acquired diseases
05/25/2010CA2195446C Growth control for cells encapsulated within bioartificial organs
05/20/2010WO2010057159A2 Antigens that elicit immune response against flavivirus and methods of using same
05/20/2010WO2010055290A1 Method
05/20/2010WO2010054807A1 Protein with promoting effects for axonal growth of neurons of central nervous system
05/20/2010WO2010032008A3 Dendritic cell modulatory molecule
05/20/2010US20100125919 Methods and compositions for modulating the mirna pathway
05/20/2010US20100125101 Immunostimulatory nucleic acid molecules
05/20/2010DE102008043654A1 Diagnostisches und/oder therapeutisches Agens, Verfahren zu seiner Herstellung und Verwendung Diagnostic and / or therapeutic agent, process for its preparation and use
05/20/2010CA2743464A1 Therapeutic and diagnostic methods relating to cancer stem cells
05/20/2010CA2740598A1 Antigens that elicit immune response against flavivirus and methods of using same
1 ... 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 ... 870